387 related articles for article (PubMed ID: 34864286)
1. Exploring brain glucose metabolic patterns in cognitively normal adults at risk of Alzheimer's disease: A cross-validation study with Chinese and ADNI cohorts.
Li TR; Dong QY; Jiang XY; Kang GX; Li X; Xie YY; Jiang JH; Han Y;
Neuroimage Clin; 2022; 33():102900. PubMed ID: 34864286
[TBL] [Abstract][Full Text] [Related]
2. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's disease.
Maass A; Landau S; Baker SL; Horng A; Lockhart SN; La Joie R; Rabinovici GD; Jagust WJ;
Neuroimage; 2017 Aug; 157():448-463. PubMed ID: 28587897
[TBL] [Abstract][Full Text] [Related]
3. β-Amyloid in blood neuronal-derived extracellular vesicles is elevated in cognitively normal adults at risk of Alzheimer's disease and predicts cerebral amyloidosis.
Li TR; Yao YX; Jiang XY; Dong QY; Yu XF; Wang T; Cai YN; Han Y
Alzheimers Res Ther; 2022 May; 14(1):66. PubMed ID: 35550625
[TBL] [Abstract][Full Text] [Related]
4. Parallel ICA of FDG-PET and PiB-PET in three conditions with underlying Alzheimer's pathology.
Laforce R; Tosun D; Ghosh P; Lehmann M; Madison CM; Weiner MW; Miller BL; Jagust WJ; Rabinovici GD
Neuroimage Clin; 2014; 4():508-16. PubMed ID: 24818077
[TBL] [Abstract][Full Text] [Related]
5. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
6. The mediational effects of FDG hypometabolism on the association between cerebrospinal fluid biomarkers and neurocognitive function.
Dowling NM; Johnson SC; Gleason CE; Jagust WJ;
Neuroimage; 2015 Jan; 105():357-68. PubMed ID: 25450107
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Group-Level and Individualized Brain Regions for Measuring Change in Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Binette AP; Vogel JW; Klein G; Borroni E; Tonietto M; Strandberg O; Mattsson-Carlgren N; Palmqvist S; Pontecorvo MJ; Iaccarino L; Stomrud E; Ossenkoppele R; Smith R; Hansson O;
JAMA Neurol; 2023 Jun; 80(6):614-623. PubMed ID: 37155176
[TBL] [Abstract][Full Text] [Related]
8. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
9. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease.
Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R;
Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896
[TBL] [Abstract][Full Text] [Related]
10. Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition.
Ozlen H; Pichet Binette A; Köbe T; Meyer PF; Gonneaud J; St-Onge F; Provost K; Soucy JP; Rosa-Neto P; Breitner J; Poirier J; Villeneuve S;
JAMA Neurol; 2022 Oct; 79(10):1025-1035. PubMed ID: 35994280
[TBL] [Abstract][Full Text] [Related]
11. The heterogeneity of asymmetric tau distribution is associated with an early age at onset and poor prognosis in Alzheimer's disease.
Lu J; Zhang Z; Wu P; Liang X; Zhang H; Hong J; Clement C; Yen TC; Ding S; Wang M; Xiao Z; Rominger A; Shi K; Guan Y; Zuo C; Zhao Q;
Neuroimage Clin; 2023; 38():103416. PubMed ID: 37137254
[TBL] [Abstract][Full Text] [Related]
12. Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.
Blazhenets G; Frings L; Sörensen A; Meyer PT;
J Nucl Med; 2021 Jun; 62(6):855-860. PubMed ID: 33097630
[TBL] [Abstract][Full Text] [Related]
13. Pathophysiology characterization of Alzheimer's disease in South China's aging population: for the Greater-Bay-Area Healthy Aging Brain Study (GHABS).
Liu Z; Shi D; Cai Y; Li A; Lan G; Sun P; Liu L; Zhu Y; Yang J; Zhou Y; Guo L; Zhang L; Deng S; Chen S; Yu X; Chen X; Zhao R; Wang Q; Ran P; Xu L; Zhou L; Sun K; Wang X; Peng Q; Han Y; Guo T
Alzheimers Res Ther; 2024 Apr; 16(1):84. PubMed ID: 38627753
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
15. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
[TBL] [Abstract][Full Text] [Related]
16. Glucose metabolism in the right middle temporal gyrus could be a potential biomarker for subjective cognitive decline: a study of a Han population.
Dong QY; Li TR; Jiang XY; Wang XN; Han Y; Jiang JH
Alzheimers Res Ther; 2021 Apr; 13(1):74. PubMed ID: 33827675
[TBL] [Abstract][Full Text] [Related]
17. Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer's disease.
Biel D; Luan Y; Brendel M; Hager P; Dewenter A; Moscoso A; Otero Svaldi D; Higgins IA; Pontecorvo M; Römer S; Steward A; Rubinski A; Zheng L; Schöll M; Shcherbinin S; Ewers M; Franzmeier N;
Alzheimers Res Ther; 2022 Nov; 14(1):166. PubMed ID: 36345046
[TBL] [Abstract][Full Text] [Related]
18. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology.
Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D
Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473
[TBL] [Abstract][Full Text] [Related]
19. Amyloid and tau signatures of brain metabolic decline in preclinical Alzheimer's disease.
Pascoal TA; Mathotaarachchi S; Shin M; Park AY; Mohades S; Benedet AL; Kang MS; Massarweh G; Soucy JP; Gauthier S; Rosa-Neto P;
Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):1021-1030. PubMed ID: 29396637
[TBL] [Abstract][Full Text] [Related]
20. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
